On December 18, Gelonghui reported that LUYE PHARMA (02186.HK) announced that the company's Board of Directors received notification from executive director and executive chairman Mr. Liu Dianbo that on December 18, 2024, through his controlled entity LUYE PHARMA Investment Limited, he purchased a total of 2 million ordinary shares in the market at an average purchase price of approximately 2.2299 Hong Kong dollars per share.

After the purchase and as of the date of this announcement, Mr. Liu holds interests in 1,261,196,703 shares, accounting for approximately 33.53% of the company's total issued share capital.

As Mr. Liu informed, he is confident in the company's growth, development, and future prospects, and may further increase his equity in the shares at an appropriate time subject to applicable laws and regulations.